Investment
Features
FeesSafety
Academy
More
Pluang+

Compare KraneShares CSI China Internet ETF (KWEB) vs Novavax Inc (NVAX) Price & Performance

KraneShares CSI China Internet ETFTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

KraneShares CSI China Internet ETF vs Novavax Inc — how do they compare? KraneShares CSI China Internet ETF trades at $27.77, while Novavax Inc trades at $7.95 (market cap $1.30B). The key difference: Novavax Inc is trading nearer its 52-week high, KraneShares CSI China Internet ETF nearer its low. Which is the better fit depends on your goals.

KWEBNVAX
Sector
Sector/ThematicHealth
52-Week High
$42.94$11.19
52-Week Low
$23.63$6.22
Market Cap
$1.30B
Enterprise Value
$879.40M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

KraneShares CSI China Internet ETF

KWEB, the KraneShares CSI China Internet ETF, trades at $28.66, up 0.99% on the day, with a bullish technical signal from moving averages and strong trend strength indicated by ADX. Recent news highlights institutional buying, China's export growth, and AI-driven factory rebounds, though RSI levels suggest potential overbought conditions. The ETF provides exposure to Chinese internet and AI companies, with performance influenced by economic policies and tech sector developments.

The outlook for KWEB is cautiously optimistic, driven by AI expansion and government support, but risks include U.S.-China tensions and regulatory shifts. Investors may find value in its tech concentration, yet must weigh geopolitical and market volatility. Analyst sentiment is mixed, balancing growth potential against structural risks.

Novavax Inc

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

About KraneShares CSI China Internet ETF

KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.

Read more on KWEB

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX